Working… Menu

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02225548
Recruitment Status : Unknown
Verified December 2017 by University of South Florida.
Recruitment status was:  Recruiting
First Posted : August 26, 2014
Last Update Posted : December 20, 2017
Information provided by (Responsible Party):
University of South Florida

Brief Summary:

The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together.

Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are not receiving complete benefit from carbidopa/levodopa.

Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic hyperplasia (BPH).

Condition or disease Intervention/treatment Phase
Parkinson's Disease Erectile Dysfunction Drug: Selegiline Drug: Tadalafil Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.
Study Start Date : September 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Selegiline and Tadalafil
Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
Drug: Selegiline
Other Names:
  • Eldepryl
  • Zelapar

Drug: Tadalafil
Other Names:
  • Cialis
  • Adcirca

Primary Outcome Measures :
  1. Changes in International Index of Erectile Function-5 (IIEF-5) score between baseline (Week 8) to end-of-study (Week 16). [ Time Frame: The IIEF-5 will be administered at Weeks 4, 8, 12 and 16 of the study. ]
    The International Index of Erectile Function (IIEF) is a widely used, multi-dimensional self-report instrument for the evaluation of male sexual function.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Diagnosis of idiopathic Parkinson's disease that is optimally treated (motor fluctuations <20% of subject's awake time). Subjects may be on levodopa therapy but must be stable at the time of entry into the study
  • Sexually active (i.e. ≥1 attempt/week) males, 40 - 64 years of age (inclusive) at time of screening
  • Diagnosis of moderate erectile dysfunction (defined according to the NIH Consensus Development Panel on Impotence) for more than 6 months and demonstrating and incomplete response to tadalafil alone
  • Subject demonstrating an IIEF-5 drug-free baseline score that is ≥ 10 but ≤ 16, and an IIEF-5 tadalafil-alone baseline score that is ≤ 18
  • Subject in a stable heterosexual relationship for at least 6 months. (2)
  • Subject motivated to seek treatment for erectile dysfunction.
  • Subject with a total serum testosterone level ≥ 300 ng/dL, with or without supplementation
  • Hoehn and Yahr Scale score of 1 - 3
  • Patient able to consent and comply with protocol requirements

Exclusion Criteria:

  • Subject unwilling to cease use of any treatment for erectile dysfunction during the study, including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications, and products purchased via the internet
  • Subject receiving dopamine agonists, nitrates, alpha-receptor blocking agents, or antihypertensive medication (see other exclusionary medications listed below)
  • Subject with a history of syncope within the last 6 months prior to screening
  • Subject with symptomatic postural hypotension (severe dizziness or fainting
  • Subject with hypotension and a resting systolic blood pressure of < 90 mmHG or hypertension with a resting systolic blood pressure > 170 mmHG or a resting diastolic blood pressure > 110 mmHG
  • Subject with any underlying cardiovascular condition, including unstable angina pectoris, which preclude sexual activity
  • Subject with a history of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to screening
  • Subject with uncontrolled atrial fibrillation/flutter at screening (defined as ventricular response rate ≥ 100 bpm)
  • Subject with a bleeding disorder
  • Subject with a history of prostatectomy because of prostate cancer, including nerve sparing techniques. Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation
  • Subject with hereditary degenerative retinal disorders such as retinitis pigmentosa
  • Subject with a history of loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), history of temporary or permanent loss of vision, including unilateral loss of vision
  • Subject with a history of congenital QT prolongation
  • Subject with a penile anatomical abnormality (e.g., penile fibrosis, fractures, or Peyronie's disease) which, in the investigator's opinion, could significantly impair sexual performance. This will be based on subject's reported medical history (penile exam not required)
  • Subject with primary hypoactive sexual desire.
  • Subject with a spinal cord injury
  • Subject with a severe chronic or acute liver disease, history of moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment
  • Subject with clinically significant chronic hematological disease which could lead to priapism such as sickle cell anemia, multiple myeloma, and leukemia
  • Subject with active peptic ulceration
  • Subject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer)
  • Subject with a history of a positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C
  • Subject with a known hypersensitivity to any component of the investigational medications, monoamine oxidase inhibitors, phosphodiesterase type 5 inhibitors or phenylethylamines
  • Subjects with a history of drug or alcohol abuse within the past 6 months
  • Subjects currently consuming ≥5 units of alcohol per day
  • Subject who is illiterate or unable to understand the Informed Consent Form, questionnaires or subject diary
  • Subject who, in the opinion of the investigator, will be noncompliant with the visit schedule or study procedures
  • Subject with any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or preclude the subject's participation in the study
  • Diagnosis of any other neurologic disease
  • Uncontrolled Diabetes (Hemoglobin A1C > 7.5)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02225548

Layout table for location contacts
Contact: Jessica Shaw, MPH 813-974-5909

Layout table for location information
United States, Florida
University of South Florida Recruiting
Tampa, Florida, United States, 33612
Contact: Tracy Jones, ARNP    813-974-5909      
Principal Investigator: Theresa Zesiewicz, MD, FAAN         
Sponsors and Collaborators
University of South Florida
Layout table for investigator information
Principal Investigator: Theresa Zesiewicz, MD, FAAN University of South Florida
Layout table for additonal information
Responsible Party: University of South Florida Identifier: NCT02225548    
Other Study ID Numbers: Sagene 2014
First Posted: August 26, 2014    Key Record Dates
Last Update Posted: December 20, 2017
Last Verified: December 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Erectile Dysfunction
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Mental Disorders
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Monoamine Oxidase Inhibitors
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs